Skip to main content
15 search results for:

Microscopic polyangiitis 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 02-08-2022 | Granulomatosis with polyangiitis | News | Article

    Sequential rituximab, mepolizumab regimen may warrant further investigation for EGPA

    Sequential treatment with rituximab followed by mepolizumab may be a promising strategy to treat the systemic and respiratory manifestations of eosinophilic granulomatosis with polyangiitis, suggest findings from an observational study.

  2. 10-02-2022 | ANCA-associated vasculitis | News | Article

    ACR, EULAR issue classification criteria for ANCA-associated vasculitis

    An international group of experts has developed and validated classification criteria for eosinophilic granulomatosis with polyangiitis, GPA, and microscopic polyangiitis.

  3. 07-07-2021 | Rituximab | News | Article

    Positive risk–benefit profile for rituximab in pediatric GPA and MPA

    Rituximab is well tolerated and shows good efficacy in children with granulomatosis with polyangiitis or microscopic polyangiitis, global phase 2a study findings indicate.

  4. 06-11-2021 | ACR 2021 | Conference coverage | Article

    Observational data show patterns of neurologic, ocular manifestations in ANCA-associated vasculitis

    The prevalence was 66.7% in the 326 people with eosinophilic granulomatosis with polyangiitis (EGPA), 24.9% in the 869 with granulomatosis with polyangiitis (GPA), and 21.8% in the 170 participants with microscopic polyangiitis (MPA).

  5. 19-11-2021 | ANCA-associated vasculitis | News | Article
    approvalsWatch

    Avacopan: EMA recommends approval for ANCA-associated vasculitis

    The complement 5a receptor inhibitor may now be given to adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.

  6. 27-10-2021 | ANCA-associated vasculitis | News | Article
    approvalsWatch

    FDA approves avacopan for ANCA-associated vasculitis

    Avacopan is recommended for the treatment of two types of ANCA-associated vasculitis – granulomatosis with polyangiitis and microscopic polyangiitis – at a dose of 30 mg twice daily, given in combination with standard therapy including glucocorticoids.

  7. 01-06-2020 | ANCA-associated vasculitis | News | Article

    MAINRITSAN3: Prolonged rituximab recommended for maintenance of remission in AAV

    The phase 3 study included 97 patients – 68 with granulomatosis with polyangiitis and 29 with microscopic polyangiitis – who were in complete remission after receiving an 18-month rituximab maintenance regimen in MAINRITSAN2.

  8. 03-02-2020 | Granulomatosis with polyangiitis | News | Article
    approvalsWatch

    Rituximab gets nod for pediatric GPA, MPA in Europe

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for rituximab should be expanded to include granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients.

  9. 07-02-2020 | Rituximab biosimilar | News | Article
    approvalsWatch

    Rituximab biosimilar recommended for European approval

    medwireNews : The EMA has adopted a positive opinion recommending approval of a new rituximab biosimilar, rituximab-pvvr, for a number of indications including rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

  10. 15-10-2019 | Granulomatosis with polyangiitis | News | Article
    approvalsWatch

    FDA approves rituximab for rare pediatric vasculitides

    medwireNews : The US FDA has expanded the indication for rituximab to include granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children aged 2 years and older.

  11. 19-06-2018 | Vasculitis | Highlight | Teaser
    Journal article

    Vasculitis associated with immune checkpoint inhibitors: A systematic review

    This study sought to conduct a systematic review of the literature to determine the number of clinical cases of vasculitis that have been reported so far with the use of immune checkpoint inhibitors, and explore the clinical commonalities that exist between these cases [ read more ]. Daxini A, Cronin K, Sreih AG. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4177-0

  12. 19-06-2018 | Vasculitis | Article

    Vasculitis associated with immune checkpoint inhibitors: A systematic review

    Daxini A, Cronin K, Sreih AG. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4177-0

  13. 02-03-2017 | ANCA-associated vasculitis | Review | Article

    Rituximab in ANCA-associated vasculitis

    The authors of this review describe the efficacy and safety of rituximab as a remission induction and maintenance therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis. Hassan RI & Gaffo AL. Curr Rheumatol Rep 2017;19:6. doi:10.1007/s11926-017-0632-1

  14. 22-09-2017 | ANCA-associated vasculitis | News | Article

    Active CV risk management needed in ANCA-associated vasculitis

    ANCA-associated vasculitis is a chronic inflammatory disease of the blood vessel wall that can be subclassified into granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, the investigators explain.

  15. 27-06-2018 | ANCA-associated vasculitis | Article

    Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis

    Kronbichler A et al. Ann Rheum Dis 2018. doi: 10.1136/annrheumdis-2017-212861

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.